Physician profile
Nicole Siems
NPI 1639404973
$1,520.08
in general payments reported to CMS, 2019-2025
26 companies · $549 in 2025
The $549 reported for 2025 was more than what 82% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $311 · 2020: $26.46 · 2021: $190 · 2022: $57.63 · 2023: $189 · 2024: $198 · 2025: $549.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $935.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $935.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $171.85 | 2023-2025 | Veozah |
| Urovant Sciences INC | $139.05 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $133.45 | 2023-2025 | Myfembree |
| Biogen, INC. | $127.25 | 2024-2025 | Zurzuvae |
| Abbvie INC. | $110.11 | 2019-2023 | Orilissa, Lo Loestrin Fe |
| Baxter Healthcare | $100.95 | 2019-2025 | Perclot |
| Bayer Healthcare Pharmaceuticals INC. | $100.03 | 2019 | |
| Sage Therapeutics, LLC | $83.80 | 2024-2025 | Zurzuvae |
| Exact Sciences Corporation | $59.12 | 2024-2025 | Cologuard Collection Kit |
| Evofem Biosciences, INC. | $51.63 | 2021-2025 | Solosec, Phexx, Phexxi |
| Avanos Medical | $49.79 | 2019 | |
| Daiichi Sankyo INC. | $44.49 | 2023 | Injectafer |
| Pfizer INC. | $42.43 | 2019-2023 | |
| Organon LLC | $33.79 | 2022-2025 | Nexplanon |
| Exeltis, USA INC. | $29.76 | 2019-2023 | Slynd |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $29.51 | 2025 | Qelbree |
| Myovant Sciences INC. | $28.05 | 2022 | |
| Allergan, INC. | $28.00 | 2019 | |
| Covidien LP | $25.29 | 2019 | |
| Celularity INC. | $25.00 | 2019 | |
| Coopersurgical, INC. | $23.22 | 2025 | Sos |
| Medtronic, INC. | $21.64 | 2021 | |
| Davol INC. | $21.14 | 2025 | Arista |
| Therapeuticsmd, INC. | $13.65 | 2019 | |
| Genzyme Corporation | $13.58 | 2025 | |
| Smith+Nephew, INC. | $13.50 | 2024 | Pico 7 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Siems listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.